肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用

doi:10.3760/cma.j.cn371439-20220614-00122

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (10): 615-618.doi: 10.3760/cma.j.cn371439-20220614-00122

肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用

王文浩^1,², 孙希瑞¹, 刘锦¹, 孙秀梅¹()

¹潍坊医学院附属医院肿瘤科，潍坊 261041
²潍坊医学院附属医院临床医学研究中心，潍坊 261041

收稿日期:2022-06-14 修回日期:2022-08-14 出版日期:2022-10-08 发布日期:2022-12-01
通讯作者: 孙秀梅 E-mail:sunxiumei8666@126.com
基金资助:
山东省医药卫生科技发展计划(202103100528)

Role of cancer-associated fibroblasts in the development and progression of breast cancer

Wang Wenhao^1,², Sun Xirui¹, Liu Jin¹, Sun Xiumei¹()

¹Department of Oncology， Affiliated Hospital of Weifang Medical University， Weifang 261041， China
²Clinical Research Center， Affiliated Hospital of Weifang Medical University， Weifang 261041， China

Received:2022-06-14 Revised:2022-08-14 Online:2022-10-08 Published:2022-12-01
Contact: Sun Xiumei E-mail:sunxiumei8666@126.com
Supported by:
Shandong Medical Science and Technology Development Project(202103100528)

摘要/Abstract

摘要：

近年来的研究表明，肿瘤微环境相较正常组织明显不同，如酶表达异常、缺氧、pH改变等。肿瘤微环境与肿瘤细胞的诱导增殖、新生血管的生成、免疫逃逸以及多药耐药的产生息息相关。肿瘤相关成纤维细胞（CAF）是肿瘤微环境中的主要基质细胞类型，其分泌的多种细胞因子在肿瘤的生长、侵袭和转移中起到了重要的作用。了解CAF在乳腺癌发生发展中的作用及其机制，有望为改善乳腺癌患者的预后提供新的作用靶点。

关键词: 肿瘤微环境, 癌相关成纤维细胞, 乳腺肿瘤, 外泌体

Abstract:

Recent studies have shown that tumor microenvironment （TME） is significantly different from normal tissues， such as the change of abnormal enzyme expression， hypoxia， pH and so on. TME is closely related to the induced proliferation of tumor cells， angiogenesis， immune escape and the production of multidrug resistance. Cancer associated fibroblasts （CAFs） are the main stromal cell types in the TME. A variety of cytokines secreted by CAFs play an important role in tumor growth， invasion and metastasis. Understanding the role and mechanism of CAFs in the development of breast cancer is expected to provide a new target for improving the prognosis of breast cancer patients.

Key words: Tumor microenvironment, Cancer-associated fibroblasts, Breast neoplasms, Exosomes

王文浩, 孙希瑞, 刘锦, 孙秀梅. 肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用[J]. 国际肿瘤学杂志, 2022, 49(10): 615-618.

Wang Wenhao, Sun Xirui, Liu Jin, Sun Xiumei. Role of cancer-associated fibroblasts in the development and progression of breast cancer[J]. Journal of International Oncology, 2022, 49(10): 615-618.

参考文献 32

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654. doi: 10.3322/caac.21654
[2]	王爱玲, 牛喜梅, 黄国福, 等. 肿瘤相关成纤维细胞在乳腺癌中的作用[J]. 国际肿瘤学杂志, 2021, 48(10): 614-617. DOI: 10.3760/cma.j.cn371439-20201208-00120. doi: 10.3760/cma.j.cn371439-20201208-00120
[3]	Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer[J]. Pharmacol Res, 2020, 153: 104683. DOI: 10.1016/j.phrs.2020.104683. doi: 10.1016/j.phrs.2020.104683
[4]	Mehraj U, Dar AH, Wani NA, et al. Tumor microenvironment promotes breast cancer chemoresistance[J]. Cancer Chemother Pharmacol, 2021, 87(2): 147-158. DOI: 10.1007/s00280-020-04222-w. doi: 10.1007/s00280-020-04222-w
[5]	毕恺欣, 张亚芬, 郝语晨, 等. 肿瘤相关成纤维细胞在乳腺癌中的研究进展[J]. 肿瘤研究与临床, 2021, 33(3): 233-236. DOI: 10.3760/cma.j.cn115355-20200218-00060. doi: 10.3760/cma.j.cn115355-20200218-00060
[6]	Suh J, Kim DH, Lee YH, et al. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling[J]. Mol Carcinog, 2020, 59(9): 1028-1040. DOI: 10.1002/mc.23233. doi: 10.1002/mc.23233
[7]	Demircioglu F, Wang J, Candido J, et al. Cancer associated fibroblast FAK regulates malignant cell metabolism[J]. Nat Commun, 2020, 11(1): 1290. DOI: 10.1038/s41467-020-15104-3. doi: 10.1038/s41467-020-15104-3 pmid: 32157087
[8]	Becker LM, O'Connell JT, Vo AP, et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer[J]. Cell Rep, 2020, 31(9): 107701. DOI: 10.1016/j.celrep.2020.107701. doi: 10.1016/j.celrep.2020.107701
[9]	于彪, 刘晴, 吴晓明. SDF-1/CXCR4在肿瘤相关成纤维细胞中的作用[J]. 基础医学与临床, 2020, 40(9): 1256-1260. DOI: 10.16352/j.issn.1001-6325.2020.09.023. doi: 10.16352/j.issn.1001-6325.2020.09.023
[10]	Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment[J]. Cancer Metastasis Rev, 2018, 37(4): 577-597. DOI: 10.1007/s10555-018-9768-3. doi: 10.1007/s10555-018-9768-3
[11]	Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis[J]. Biochem Soc Trans, 2017, 45(1): 229-236. DOI: 10.1042/BST20160387. doi: 10.1042/BST20160387
[12]	Ren J, Smid M, Iaria J, et al. Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression[J]. Breast Cancer Res, 2019, 21(1): 109. DOI: 10.1186/s13058-019-1194-0. doi: 10.1186/s13058-019-1194-0 pmid: 31533776
[13]	Eckhardt BL, Cao Y, Redfern AD, et al. Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis[J]. Cancer Res, 2020, 80(6): 1304-1315. DOI: 10.1158/0008-5472.CAN-19-0743. doi: 10.1158/0008-5472.CAN-19-0743 pmid: 31941699
[14]	Insua-Rodríguez J, Oskarsson T. The extracellular matrix in breast cancer[J]. Adv Drug Deliv Rev, 2016, 97: 41-55. DOI: 10.1016/j.addr.2015.12.017. doi: 10.1016/j.addr.2015.12.017
[15]	Hong JT, Son DJ, Lee CK, et al. Interleukin 32, inflammation and cancer[J]. Pharmacol Ther, 2017, 174: 127-137. DOI: 10.1016/j.pharmthera.2017.02.025. doi: 10.1016/j.pharmthera.2017.02.025
[16]	Sloot YJE, Smit JW, Joosten LAB, et al. Insights into the role of IL-32 in cancer[J]. Semin Immunol, 2018, 38: 24-32. DOI: 10.1016/j.smim.2018.03.004. doi: S1044-5323(17)30079-9 pmid: 29747940
[17]	Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling[J]. Cancer Lett, 2019, 442: 320-332. DOI: 10.1016/j.canlet.2018.10.015. doi: S0304-3835(18)30629-3 pmid: 30391782
[18]	Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10(1): 4375. DOI: 10.1038/s41467-019-12370-8. doi: 10.1038/s41467-019-12370-8 pmid: 31558756
[19]	Shani O, Vorobyov T, Monteran L, et al. Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity[J]. Cancer Res, 2020, 80(23): 5317-5329. DOI: 10.1158/0008-5472.CAN-20-2116. doi: 10.1158/0008-5472.CAN-20-2116 pmid: 33023944
[20]	Barrett RL, Puré E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy[J]. Elife, 2020, 9: e57243. DOI: 10.7554/eLife.57243. doi: 10.7554/eLife.57243
[21]	Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer[J]. Cancer Discov, 2020, 10(9): 1330-1351. DOI: 10.1158/2159-8290.CD-19-1384. doi: 10.1158/2159-8290.CD-19-1384 pmid: 32434947
[22]	Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J]. Cancer Cell, 2018, 33(3): 463-479.e10. DOI: 10.1016/j.ccell.2018.01.011. doi: S1535-6108(18)30011-4 pmid: 29455927
[23]	Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment[J]. Front Immunol, 2019, 10: 1835. DOI: 10.3389/fimmu.2019.01835. doi: 10.3389/fimmu.2019.01835 pmid: 31428105
[24]	Pinheiro PF, Justino GC, Marques MM. NKp30—a prospective target for new cancer immunotherapy strategies[J]. Br J Pharmacol, 2020, 177(20): 4563-4580. DOI: 10.1111/bph.15222. doi: 10.1111/bph.15222
[25]	Su S, Chen J, Yao H, et al. CD10⁺GPR77⁺ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness[J]. Cell, 2018, 172(4): 841-856.e16. DOI: 10.1016/j.cell.2018.01.009. doi: 10.1016/j.cell.2018.01.009
[26]	Zhai L, Spranger S, Binder DC, et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy[J]. Clin Cancer Res, 2015, 21(24): 5427-5433. DOI: 10.1158/1078-0432.CCR-15-0420. doi: 10.1158/1078-0432.CCR-15-0420 pmid: 26519060
[27]	Martinez-Outschoorn UE, Goldberg A, Lin Z, et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells[J]. Cancer Biol Ther, 2011, 12(10): 924-938. DOI: 10.4161/cbt.12.10.17780. doi: 10.4161/cbt.12.10.17780 pmid: 22041887
[28]	Bu L, Baba H, Yasuda T, et al. Functional diversity of cancer-associated fibroblasts in modulating drug resistance[J]. Cancer Sci, 2020, 111(10): 3468-3477. DOI: 10.1111/cas.14578. doi: 10.1111/cas.14578
[29]	Chan YT, Lai AC, Lin RJ, et al. GPER-induced signaling is essential for the survival of breast cancer stem cells[J]. Int J Cancer, 2020, 146(6): 1674-1685. DOI: 10.1002/ijc.32588. doi: 10.1002/ijc.32588
[30]	Dou D, Ren X, Han M, et al. Cancer-associated fibroblasts-derived exosomes suppress immune cell function in breast cancer via the miR-92/PD-L1 pathway[J]. Front Immunol, 2020, 11: 2026. DOI: 10.3389/fimmu.2020.02026. doi: 10.3389/fimmu.2020.02026 pmid: 33162971
[31]	Sung JS, Kang CW, Kang S, et al. ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts[J]. Oncogene, 2020, 39(3): 664-676. DOI: 10.1038/s41388-019-1014-0. doi: 10.1038/s41388-019-1014-0 pmid: 31534187
[32]	Yang SS, Ma S, Dou H, et al. Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment[J]. Exp Cell Res, 2020, 391(2): 111983. DOI: 10.1016/j.yexcr.2020.111983. doi: 10.1016/j.yexcr.2020.111983

肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用

Role of cancer-associated fibroblasts in the development and progression of breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	傅旖, 马辰莺, 张露, 周菊英. 生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	刘博翰, 黄俊星. 液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[6]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	刘筱迪, 苏剑飞, 张静娴, 卫雪芹, 贾英杰. 髓源性抑制细胞在肿瘤血管生成中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 50-54.
[8]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[9]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[10]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[11]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[12]	张渊, 白芷玉, 李琪, 冯勤梅. 外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488.
[13]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[14]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[15]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.